Rabisin 1Ml

Target species Dogs and cats. Indications for use For active immunisation of dogs and cats, to reduce mortality and clinical signs due to rabies infection. Immunity has been demonstrated 1 month after primary vaccination, and has been shown to persist up to the first booster dose, (1 year after primary vaccination) and up to 3 years following booster vaccination. Contra-indications None. Special warnings for each target species Do not vaccinate unhealthy animals. Special precautions for use in animals Where a dog or a cat was vaccinated before 12 weeks of age, the primary vaccination scheme should be completed by an injection given at 12 weeks of age or older. Special precautions to be taken by the person administering the product to animals In the case of accidental self-injection, seek medical advice immediately and show the package leaflet or label to the physician. Adverse reactions Vaccination may sometimes induce a local reaction, as a small and transient swelling at the injection site (usually 2-3 cm diameter, persisting mostly up to 2 weeks, rarely up to 4 weeks). Vaccination may exceptionally induce an anaphylactoid (hypersensitivity) reaction. In such a case, symptomatic treatment should be provided. Use during pregnancy, lactation or lay Can be used during pregnancy. Interactions Safety and efficacy data are available which demonstrate that this vaccine can be administered the same day but not mixed with Boehringer Ingelheim’s Purevax non-adjuvanted vaccines for cats. In the case of products administered parenterally, the products should be given at different sites. No information is available on the safety and efficacy of this vaccine when used with any other product except the products mentioned above. A decision to use this vaccine before or after any other product therefore needs to be decided on a case by case basis.